Literature DB >> 35396937

Polymorphisms of an oncogenic gene, mesothelin, predict the risk and prognosis of gastric cancer in a Chinese Han population.

Kuan Shen1, Kanghui Liu1, Yuanhang Wang1, Peidong Ni1, Jian Xiao1, Fan Hao1, Xinyi Zhou1, Zekuan Xu1, Li Yang2,3.   

Abstract

Mesothelin (MSLN) is a cell surface protein associated with tumor invasion and metastasis. This study aims to explore the biological function of MSLN in gastric cancer and to evaluate the association of MSLN polymorphism (rs3764247, rs3764246, rs12597489, rs1057147, rs3765319) with the risk and prognosis of gastric cancer. Small interfering RNA (siRNA) transfection and MSLN overexpression were performed in human gastric cancer cell lines, respectively. The proliferation of tumor cells was evaluated by Cell counting kit 8(CCK-8) and colony formation assay. Wound healing assay and transwell assay were used to elucidate gastric cancer cell migration and invasion rates. We conducted a case-control study involving 860 patients with gastric cancer and 870 controls. All mutation sites were genotyped by PCR-LDR sequencing. First, our study revealed the cancer-promoting role of MSLN in gastric cancer. Second, we also demonstrated that rs3764247 and rs3764246 were associated with a reduced risk of gastric cancer (OR = 0.83, p = 0.010; OR = 0.84, p = 0.011; respectively). The clinicopathological analysis further showed that rs3764247 was closely related to T stage, vascular infiltration, and HER2 expression. In addition, in the survival analysis of 392 patients with gastric cancer, patients with rs3764247 CC genotype had poorer survival than patients with AA + AC genotype after adjusting for age, sex, TNM stage, and Lauren classification (HR = 2.07, p = 0.029). Our findings indicated that MSLN could be an oncogene whose polymorphisms were closely related to the risk and prognosis of gastric cancer.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Cancer prognosis; Cancer risk; Gastric cancer; Mesothelin; Single nucleotide polymorphism

Mesh:

Substances:

Year:  2022        PMID: 35396937     DOI: 10.1007/s00204-022-03290-6

Source DB:  PubMed          Journal:  Arch Toxicol        ISSN: 0340-5761            Impact factor:   6.168


  40 in total

Review 1.  Epidemiologic trends in esophageal and gastric cancer in the United States.

Authors:  Linda Morris Brown; Susan S Devesa
Journal:  Surg Oncol Clin N Am       Date:  2002-04       Impact factor: 3.495

2.  Mesothelin overexpression promotes autocrine IL-6/sIL-6R trans-signaling to stimulate pancreatic cancer cell proliferation.

Authors:  Uddalak Bharadwaj; Christian Marin-Muller; Min Li; Changyi Chen; Qizhi Yao
Journal:  Carcinogenesis       Date:  2011-04-23       Impact factor: 4.944

3.  Mesothelin is not required for normal mouse development or reproduction.

Authors:  T K Bera; I Pastan
Journal:  Mol Cell Biol       Date:  2000-04       Impact factor: 4.272

4.  Mesothelin expression correlates with prolonged patient survival in gastric cancer.

Authors:  Kenji Baba; Sumiya Ishigami; Takaaki Arigami; Yoshikazu Uenosono; Hiroshi Okumura; Masataka Matsumoto; Hiroshi Kurahara; Yuto Uchikado; Yoshiaki Kita; Yuko Kijima; Masaki Kitazono; Hiroyuki Shinchi; Shinichi Ueno; Shoji Natsugoe
Journal:  J Surg Oncol       Date:  2011-07-20       Impact factor: 3.454

5.  Mesothelin enhances invasion of ovarian cancer by inducing MMP-7 through MAPK/ERK and JNK pathways.

Authors:  Ming-Cheng Chang; Chi-An Chen; Pao-Jen Chen; Ying-Cheng Chiang; Yu-Li Chen; Tsui-Lien Mao; Han-Wei Lin; Wen-Hsien Lin Chiang; Wen-Fang Cheng
Journal:  Biochem J       Date:  2012-03-01       Impact factor: 3.857

6.  Cancer statistics in China, 2015.

Authors:  Wanqing Chen; Rongshou Zheng; Peter D Baade; Siwei Zhang; Hongmei Zeng; Freddie Bray; Ahmedin Jemal; Xue Qin Yu; Jie He
Journal:  CA Cancer J Clin       Date:  2016-01-25       Impact factor: 508.702

7.  Association of genetic variants in the 3'-untranslated region of the mesothelin (MSLN) gene with ovarian carcinoma.

Authors:  Amoura M Abou-El-Naga; Salwa M Abo El-Khair; Ashraf Z Mahmoud; Mohamed Hamza; Rami M Elshazli
Journal:  J Biochem Mol Toxicol       Date:  2020-09-30       Impact factor: 3.642

8.  Luminal membrane expression of mesothelin is a prominent poor prognostic factor for gastric cancer.

Authors:  T Einama; S Homma; H Kamachi; F Kawamata; K Takahashi; N Takahashi; M Taniguchi; T Kamiyama; H Furukawa; Y Matsuno; S Tanaka; H Nishihara; A Taketomi; S Todo
Journal:  Br J Cancer       Date:  2012-05-29       Impact factor: 7.640

9.  Regulation of invasion and peritoneal dissemination of ovarian cancer by mesothelin manipulation.

Authors:  Ricardo Coelho; Sara Ricardo; Ana Luísa Amaral; Yen-Lin Huang; Mariana Nunes; José Pedro Neves; Nuno Mendes; Mónica Nuñez López; Carla Bartosch; Verónica Ferreira; Raquel Portugal; José Manuel Lopes; Raquel Almeida; Viola Heinzelmann-Schwarz; Francis Jacob; Leonor David
Journal:  Oncogenesis       Date:  2020-07-01       Impact factor: 7.485

10.  Mesothelin binding to CA125/MUC16 promotes pancreatic cancer cell motility and invasion via MMP-7 activation.

Authors:  Shih-Hsun Chen; Wei-Chien Hung; Pu Wang; Colin Paul; Konstantinos Konstantopoulos
Journal:  Sci Rep       Date:  2013       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.